Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hAECs for COVID-19 related respiratory failure
ACTRN12620000676910Phase 2Not yet recruiting
- Sponsor
- Monash Health
- Start
- Jun 2020
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of human amniotic epithelial stem cells in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Monash Health. Primary endpoints: Ventilator-free days score and Daily change in P/F ratio. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
human amniotic epithelial stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12620000676910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000676910.